Table 4 Factors predicting variceal bleeding episodes in the entire set of patients with PVTT (n = 206)

Age (years)

55.6 ± 9.5

52.9 ± 7.9

0.979

0.916–1.045

0.523

Male

173 (88.3)

8 (80.0)

2.023

0.428–9.566

0.374

Hypertension

42 (21.4)

2 (20.0)

0.997

0.210–4.723

0.997

HBV infection

173 (88.3)

10 (100.0)

 A (reference)

174 (88.8)

10 (100.0)

 B

22 (11.2)

0 (0.0)

NSBBs

36 (18.4)

2 (20.0)

1.283

0.270–6.090

0.754

PT (INR)

1.1 ± 0.1

1.2 ± 0.1

1.956

1.191–3.210

0.008

Creatinine (mg/dl)

0.9 ± 0.1

0.9 ± 0.2

0.774

0.112–5.355

0.795

Platelet count (×10³/uL)

140.1 ± 64.2

127.2 ± 51.4

0.996

0.985–1.007

0.528

AST (IU/L)

57.5 ± 48.8

48.3 ± 26.4

0.995

0.976–1.013

0.576

ALT (IU/L)

43.9 ± 40.8

40.2 ± 29.1

0.997

0.975–1.018

0.758

Ascites

18 (9.2)

0 (0.0)

 Single (reference)

109 (55.6)

6 (60.0)

1.0

–

–

 Multiple

87 (44.4)

4 (40.0)

1.151

0.316–4.194

0.831

 Tumor size (cm)

7.1 ± 3.5

8.4 ± 4.9

1.237

0.258–5.929

0.790

 Serum AFP (ng/ml)

13,429.2 ± 45,167.2

8230.8 ± 18,268.5

1.154

0.976–1.364

0.093

 Extrahepatic metastasis

41 (20.9)

2 (20.0)

0.998

0.976–1.021

0.875

 Vp2 (reference)

74 (37.7)

2 (20.0)

1.0

–

–

 Vp3

45 (23.0)

3 (30.0)

2.464

0.406–14.924

0.327

 Vp4

77 (39.3)

5 (50.0)

2.965

0.567–15.497

0.198

 TACE

133 (67.9)

7 (70.0)

1.174

0.302–4.574

0.817

 Radiotherapy

52 (26.5)

2 (20.0)

0.753

0.160–3.554

0.720

 Sorafenib

9 (4.6)

3 (30.0)

11.615

2.809–48.030

0.001

5.676

1.273–25.300

0.023

High-risk varices

49 (25.0)

9 (90.0)

31.323

3.928–249.782

0.001

26.432

3.230–216.289

0.002